Palbociclib plus fulvestrant clinical outcomes PALOMA-3

Clinical Outcomes

In the PALOMA-3 trial, palbociclib plus fulvestrant improved progression-free survival by approximately 5 months, overall survival by 6.9 months, and doubled time to chemotherapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer progressing on prior endocrine therapy, with a manageable safety profile dominated by reversible hematologic toxicity.

Abstract

The PALOMA-3 trial demonstrated substantial clinical benefit for palbociclib plus fulvestrant in hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. Across multiple analyses with follow-up extending to 73.3 months, palbociclib plus fulvestrant consistently improved median progression-free survival by approximately 5 months compared to placebo plus fulvestrant (9.2-11.2 months vs 3.8-4.6 months, HR 0.42-0.50, p<0.001). The most recent analysis showed median overall survival of 34.8 months versus 28.0 months (HR 0.81, 95% CI 0.65-0.99), with greater benefit observed in patients with endocrine-sensitive disease who had not received prior chemotherapy for metastatic disease (39.3 vs 29.7 months, HR 0.72). Palbociclib plus fulvestrant doubled the median time to receipt of chemotherapy (17.6 vs 8.8 months, HR 0.58, p<0.001).

The safety profile was characterized by predictable hematologic toxicity, with grade 3-4 neutropenia occurring in 52-65% of patients but febrile neutropenia remaining low at 0.6-4.1%. Treatment discontinuation rates due to adverse events were minimal (2.0-2.6%), and dose intensity was maintained at 89.7% despite frequent dose modifications. Clinical benefit was consistent across menopausal status, geographic populations including Asian patients (HR 0.485), and molecular subtypes, with palbociclib providing benefit regardless of ESR1, PIK3CA, or TP53 mutation status. Quality of life was maintained with no significant deterioration from baseline.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Records from Elicit search

• n = 200

Papers screened using:

• Patient Population - Disease Type,

• Intervention Type,

• Clinical Outcomes Reported,

• Study Design,

• Patient Age,

• Combination Therapy Focus,

• Human Clinical Evidence,

• Full Publication Available

• n = 200

Papers screened out

• n = 190

Papers included for extraction

• n = 10

Data extraction

We asked a large language model to extract each data column below from each paper.

Efficacy Outcomes:

• Primary endpoint results (progression-free survival): median PFS, hazard ratio, 95% CI, p-value
• Secondary efficacy endpoints (overall survival, overall response rate, clinical benefit rate): median values, hazard ratios, 95% CIs, p-values
• Time to key outcomes (time to chemotherapy, time to next treatment)

Safety Profile:

• Most common adverse events (any grade and grade 3-4) with percentages for each treatment arm
• Serious adverse events and adverse events leading to discontinuation, dose reduction, or dose delays

Patient Characteristics:

• Sample size per treatment arm
• Demographics (median age, menopausal status distribution)
• Disease characteristics (HR/HER2 status, visceral disease percentage, bone-only disease, ECOG performance status)

Subgroup Analyses:

• Extract results of all subgroup analyses performed in PALOMA-3 for palbociclib plus fulvestrant, including:
• Pre-specified subgroups: endocrine sensitivity (sensitive vs resistant), menopausal status (pre/peri vs post), visceral disease (present vs absent)

Follow-up Duration:

• Median follow-up duration for the overall population
• Data cutoff date
• Percentage of events observed for primary and secondary endpoints

Treatment Details:

• Extract specific treatment regimen details for PALOMA-3, including:
• Palbociclib dosing (dose, schedule, route of administration)
• Fulvestrant dosing and administration schedule

Biomarker Analysis:

• Biomarker or molecular analysis results from PALOMA-3, including:
• Circulating tumor DNA (ctDNA) analysis
• ESR1, PIK3CA, TP53 mutation analysis and correlation with outcomes

Patient-Reported Outcomes:

• Extract patient-reported outcome measures and quality of life data from PALOMA-3.

Results

Characteristics of Included Studies

The review included 10 publications reporting results from the PALOMA-3 trial, a randomized, double-blind, phase 3 study evaluating palbociclib plus fulvestrant versus placebo plus fulvestrant in patients with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.

The PALOMA-3 trial randomized 521 women with hormone receptor-positive, HER2-negative metastatic breast cancer in a 2:1 ratio to receive palbociclib plus fulvestrant (n=347) or placebo plus fulvestrant (n=174). Patients were stratified by sensitivity to previous hormonal therapy, menopausal status, and presence of visceral metastasis.

Progression-Free Survival

The primary endpoint of progression-free survival (PFS) showed consistent and substantial improvement with palbociclib plus fulvestrant across multiple analyses. Interim analyses reported median PFS of 9.2 months for palbociclib plus fulvestrant versus 3.8 months for placebo plus fulvestrant (HR 0.42, 95% CI 0.32-0.56, p<0.001). The final analysis confirmed these findings with median PFS of 9.5 months versus 4.6 months (HR 0.46, 95% CI 0.36-0.59, p<0.0001). The most recent long-term analysis reported median PFS of 11.2 months versus 4.6 months (HR 0.50, 95% CI 0.40-0.62, one-sided p<0.0001).

In the Asian subgroup, median PFS was not reached for palbociclib plus fulvestrant compared to 5.8 months for placebo plus fulvestrant (HR 0.485, 95% CI 0.270-0.869, p=0.0065), demonstrating consistent benefit across geographic populations.

Overall Survival

Overall survival (OS) analyses evolved with longer follow-up. The initial prespecified OS analysis with 44.8 months of follow-up showed median OS of 34.9 months for palbociclib plus fulvestrant versus 28.0 months for placebo plus fulvestrant (HR 0.81, 95% CI 0.64-1.03, p=0.09), representing a 6.9-month absolute difference. While this did not achieve statistical significance in the overall population, the benefit was more pronounced in the subset of 410 patients with sensitivity to previous endocrine therapy, where median OS was 39.7 months versus 29.7 months (HR 0.72, 95% CI 0.55-0.94), representing a 10.0-month absolute difference.

The updated exploratory analysis with 73.3 months of median follow-up (75% of enrolled patients deceased) confirmed median OS of 34.8 months in the palbociclib group versus 28.0 months in the placebo group (HR 0.81, 95% CI 0.65-0.99). The 6-year OS rate was 19.1% for palbociclib plus fulvestrant compared to 12.9% for placebo plus fulvestrant.

Time to Subsequent Therapy

Palbociclib plus fulvestrant significantly delayed the need for chemotherapy. Median time to receipt of chemotherapy was 17.6 months for palbociclib plus fulvestrant compared to 8.8 months for placebo plus fulvestrant (HR 0.58, 95% CI 0.47-0.73, p<0.001), effectively doubling the chemotherapy-free interval.

Safety and Tolerability

The safety profile of palbociclib plus fulvestrant was characterized predominantly by asymptomatic hematologic toxicity. The overall rate of any grade adverse events was 98% for palbociclib plus fulvestrant versus 89% for placebo plus fulvestrant, with grade 3-4 events occurring in 70% versus 18% of patients, respectively.

Neutropenia occurred early, with a median onset time for first episode of grade ≥3 neutropenia of 15 days and median duration of 7 days. Importantly, febrile neutropenia rates remained low at 0.6% in most analyses, with the Asian subgroup showing a slightly higher rate of 4.1%. Concurrent grade ≥3 infections occurred in only 1% of patients with grade ≥3 neutropenia.

Subgroup Analyses

Subgroup analyses demonstrated consistent benefit of palbociclib plus fulvestrant across pre-specified stratification factors.

For the endocrine sensitivity subgroup, patients with sensitivity to previous endocrine therapy showed particularly favorable outcomes with median OS of 39.7 months versus 29.7 months (HR 0.72, 95% CI 0.55-0.94). This represented a clinically meaningful 10-month OS advantage.

Prior therapy significantly modified outcomes. Among 344 patients without prior chemotherapy for advanced breast cancer, median OS was 39.3 months (95% CI 34.5-44.4) versus 29.7 months (95% CI 23.8-35.5) with placebo (HR 0.72, 95% CI 0.55-0.94).

Biomarker Analyses

Circulating tumor DNA (ctDNA) analysis was performed using a targeted panel of 17 genes in 331 patients at day 1. PIK3CA mutations were detected in plasma DNA of 129 patients (33%) in the earlier analysis, with the updated analysis showing prevalence at day 1 of 21.8% for ESR1, 16.6% for PIK3CA, and 15.4% for TP53 mutations.

Patient-Reported Outcomes

Patient-reported outcomes were assessed as a secondary endpoint, though detailed results were not extensively reported in most publications. In the Asian subgroup analysis, global quality of life was maintained with no statistically significant changes from baseline observed for patient-reported outcome scores with palbociclib plus fulvestrant.